🔴 Problem Identified
European venture capital has shifted away from its original purpose of supporting high-risk, innovative ventures, becoming more akin to small-cap private equity focused on predictable returns. This 'Safe Bet Syndrome' has led to decreased investment in groundbreaking technologies and an emphasis on established business models, resulting in a funding gap for transformative innovations. The preference for revenue traction and proven teams undermines potential high returns, mirroring a trend towards conservative risk profiles reminiscent of buyout funds. To foster genuine innovation, Europe needs new forms of risk capital with long-term horizons willing to invest in promising but uncertain ideas, moving beyond the current VC structures.
💡 Proposed Solution
Venture Catalyst Fund (VCF) would serve as a patient capital provider, focusing on early-stage, high-risk innovations in academic research and technology-oriented startups. By adopting a long-term investment horizon of 15-20 years, VCF would actively seek out and support projects with the potential for disruptive impact, providing the necessary funding and strategic mentorship to navigate the commercialization process.
Market Size
Medium
Difficulty
Medium
Time to MVP
6+ months
Investment
High
Unlock Full Analysis
Get competitor analysis, cost breakdowns, implementation roadmaps, and AI-powered next steps.
Create Free AccountAlready have an account? Log in
Quick Overview
Target Audience
Early-stage startups emerging from academic institutions, particularly in technology and biotech sectors, and innovative entrepreneurs with moonshot ideas that lack access to traditional VC funding.
Revenue Potential
€500,000 - €2 million
Competition
Medium
Key Advantage
VCF would differentiate itself by committing to high-risk investments and providing tailored mentorship and resources, w...